tbuckley/cabot-search huggingface dataset:
Fellowships Grants and Awards
Journal: Environmental Health Perspectives (2002)

The NIEHS invites applications to study environmental agents that cause cardiovascular malformations (CVMs).The purposes of this PA are to stimulate research to characterize environmental agents that cause alterations in the development of the cardiovascular system and thereby lead to CVMs, and to investigate the cellular and molecular mechanisms involved in the development of these CVMs.The use of mammalian and nonmammalian animal models, including transgenic and gene knockout animal models, and of state-of-the-art molecular biology techniques such as genomics and proteomics is encouraged, as well as collaborations between environmental health scientists and developmental biologists, to develop research programs to address the high rate of CVMs.CVMs are the most common type of birth defect among live births in the United States, occurring in approximately 0.8% of live births.The most common types of CVMs include atrial or ventricular septal defects, transposition of the great vessels, persistent truncus arteriosus, teratology of Fallot, and coarctations.Despite the importance of these in malformations, in terms both of human suffering and cost to the health care system, the causes of most cases of CVMs are not known.Etiologic factors that have been identified include genetics, maternal diseases such as diabetes, certain drugs such as phenytoin and cocaine, and dietary factors such as folic acid deficiency, vitamin A excess, and copper deficiency.In addition, certain environmental chemicals have been shown to be associated with cardiac malformations.For instance, in one large epidemiologic study of cardiac malformations, the Baltimore-Washington Infant Study, exposure to such environmental factors as paints, solvents, degreasers, and pesticides was associated with increased cardiac malformations.Epidemiologic studies have also reported CVM associations with air pollutants (ozone and carbon monoxide) and trichloroethylene (TCE).In addition, environmental contaminants such as TCE, bisdiamine, and dioxin have been shown to be cardiac teratogens in animal studies.Despite the evidence for an environmental role in CVMs, the list of environmental agents tested for teratogenic effects on the heart is limited, and relatively little research has been done on the cellular and molecular basis of the teratogenic effects of environmental agents or on the possible interactions between environmental exposures and other factors such as diet and genetics.Recent advances in genomic and molecular biology technology and in the understanding of the development of the fetal heart make this an opportune time to initiate such studies.Specific areas of interest to the NIEHS include, but are not limited to, the following: 1) characterization of new potential environmental cardioteratogens that would include the types of CVMs induced, dose-response evaluation, identification of specific windows of vulnerability to the agent, and development of preliminary data for further mechanistic studies; 2) use of forward and reverse mutagenesis studies
Plasmapheresis Therapy in Macroglobulinemia
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FDA Approval of a Haemophilus b Conjugate Vaccine Combined by Reconstitution With an Acellular Pertussis Vaccine
Journal: JAMA (1997)

On September 27, 1996, the Food and Drug Administration (FDA) licensed a Haemophilus b Conjugate Vaccine (ActHIB) combined by reconstitution with diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) (Tripedia) for use as the fourth dose in the childhood vaccination series. This combination vaccine will be sold under the trade name TriHIBit. On July 31, 1996, Tripedia was licensed for the initial four doses of the diphtheria, tetanus, and pertussis vaccination series. TriHIBit is the first vaccine to be licensed in the United States that combines DTaP with a Haemophilus b Conjugate Vaccine.
Abortion and maternal deaths.
Journal: BMJ (1976)

rather than the failure of the health authority or the district management team.The superin- tendent who speaks out on behalf of his hospital runs the risk of incurring the dis- pleasure and pique of authorities.If the post of superintendent is as incompatible with the new system and as redundant as is widely claimed it would appear reason- able, logical, and fair to give it an appropriate burial on a national basis with guidance from the DHSS on the recompense of those who, through no fault of their own, were appointed to such posts and now find themselves in an uncertain and embarrassing position.
Challenge to osteopathic education. Returning to its primary care roots
Authors: M Cummings
Journal: JAMA (1992)

<h3>THE OSTEOPATHIC TRADITION: A PRIMARY CARE ORIENTATION</h3> Of the 15 accredited colleges of osteopathic medicine, 10 were founded between 1969 and 1981. Of these 10, six are state-supported medical colleges, which, like the others, were originally created with a generalist focus. The primary care orientation of the osteopathic physician has been reinforced by the medical college curriculum and clinical education and by the prominent roles given to generalist physicians. The osteopathic educational system helped foster primary care education through its orientation to the health care needs of the community—ambulatory clinics and smaller hospitals were staffed by competent generalists (role models); the patient population was diverse; and clinical education emphasized prevention, ambulatory medicine, and acquisition of broad-based medical knowledge and practical skills. Students traditionally received their clinical training through the network of about 100 osteopathic hospitals, located chiefly in small communities and in America's inner cities. They had limited opportunities to
A phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group (GOG) study
Authors: M. A. Powell, V. L. Filiaci, P. G. Rose, R. S. Mannel, P. Hanjani, K. DeGeest, B. E. Miller, N. Susumu, F. R. Ueland
Journal: Journal of Clinical Oncology (2009)

5515 Background: Both platinum and taxane compounds have demonstrated activity in uterine carcinosarcoma (malignant mixed Mullerian tumor). Ifosfamide plus paclitaxel is the regimen supported by randomized phase III trials through the GOG. However, the toxicity, multi-day schedule, and limited activity of this regimen indicate that development of other regimens is still needed. The primary aims of this prospective study were to estimate the antitumor activity and toxicity of paclitaxel plus carboplatin in patients with uterine carcinosarcomas. Methods: Eligible patients had advanced stage (III or IV), persistent, or recurrent measurable disease with histologic confirmation of the primary tumor, no prior chemotherapy, and a GOG Performance Status of 2 or better. At entry hematologic and all other labs were within pre-defined limits. Patients received the combination of paclitaxel 175 mg/m2 IV over 3 hours plus carboplatin (AUC 6) IV over 30 minutes every 3 weeks until disease progression or adverse effects prohibit further therapy. The primary endpoint of confirmed response was assessed by RECIST criteria. CTCAE v3 was used to grade adverse events. This study used an optimal but flexible two-stage design with early stopping guidelines intended to limit patient accrual to inactive treatments. Forty to 47 eligible patients were targeted for accrual. Central pathology review (CPR) is still pending for 5 patients. Results: Fifty-five patients were entered on study with 9 being excluded from analysis; 7 with unconfirmed diagnosis at CPR and 2 were never treated. Treatment was generally tolerated with expected hematologic toxicity and minimal non-hematologic grade 4 toxicity (1 cardiovascular and 2 pain) with 59% of patients completing 6 or more cycles of chemotherapy. The proportion of patients with confirmed complete and partial responses were 11% and 41%, respectively (52%; 95% CI 37%-67%). Additionally 4% experienced an unconfirmed response and 26% had stable disease. Conclusions: Paclitaxel plus carboplatin demonstrates anti-tumor activity against uterine carcinosarcoma with acceptable toxicity and warrants further evaluation in phase III randomized trials. No significant financial relationships to disclose.
TEXAS AND "DIPLOMA MILLS."
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Medical Society of New Jersey since 1766
Authors: F. B. Rogers
Journal: JAMA (1966)

Chronologically oldest state medical society in the United States, The Medical Society of New Jersey was founded on July 23, 1766, at a meeting held in New Brunswick. The 17 physicians who adopted the "instruments of association" on that day met in response to a notice, published in the<i>New York Mercury</i>, June 27, which read: A considerable number of the practitioners of physic and surgery in New Jersey, having agreed to form a society for the advancement of their profession and promotion of the public good, request and invite every gentleman of the profession in the province to attend a meeting at Mr. Duff's, in the city of New Brunswick, on Wednesday, the 23d of July, at which time and place, the Constitution and Regulations of the Society are to be settled and subscribed. The group elected as its first president the Reverend Robert McKean, pastor and physician who
Outbreak of Legionnaires' Disease Among Automotive Plant Workers—Ohio, 2001
Journal: JAMA (2001)

During March 12-15, 2001, four cases of Legionnaires' disease (LD) among workers at an automotive engine manufacturing plant (plant X) were reported to the Cuyahoga County Board of Health, Cleveland, Ohio; all four diagnoses were confirmed by Legionella urine antigen. Illness onset among the four workers occurred during March 2-4; two workers died. Beginning March 14, CDC assisted state and local health departments with an investigation to identify new cases and potential sources of Legionella transmission in the plant. This report summarizes the investigation; findings indicate an epidemiologic association with exposure to one of the plant finishing lines but did not identify a specific source.
Controlling the electrocution hazard in the hospital
Authors: S. R. Arbeit
Journal: JAMA (1972)

The hospitalized patient is in jeopardy from the electrical devices that surround or are attached to him. He is at a special risk because he is frequently grounded by monitoring devices and his protective skin barrier breached. Poorly designed electrical devices and inadequate or improper grounding of the hospital electrical system or of the equipment add to his danger. The adoption of the following steps will reduce this hazard: (1) Never ground the patient; ground everything else. (2) The building wiring and electrical supply, especially its grounding system should be brought up to modern standards. (3) All new electrical equipment should be evaluated for safety and tested before use. (4) An ongoing electrical preventive maintenance program should be established. Isolation power supplies ("safe power centers") have been proposed to reduce or eliminate these hazards but are not recommended.
The Environment: People Pollution
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Human Drug Discrimination and Multiple Chemical Sensitivity: Caffeine Exposure as an Experimental Model
Authors: Thomas Eissenberg, Roland R. Griffiths
Journal: Environmental Health Perspectives (1997)

Multiple chemical sensitivity is a controversial diagnosis.Rigorous, controlled, laboratory-based research can reduce this controversy and lead to potential clinical confirmatory tests.The literature on human caffeine discrimination provides a rigorous methodology that can address reports that patients who suffer multiple chemical sensitivity (MCS) are sensitive to usually well- tolerated chemical doses; the studies require patients to discriminate caffeine from placebo under double-blind conditions.Several issues relevant to the conduct of caffeine discrimination studies using MCS patients as subjects are addressed; these issues include study design, determination of safe and tolerable training doses, and discrimination training.Such research will benefit patients and clinicians dealing with a diagnosis of MCS.
PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.
Authors: Jean Abraham, Anne-Laure Vallier, Wendi Qian, Andrea Machin, Louise Grybowicz, Stanly Thomas, Caron Harvey, Karen McAdam, Luke Hughes-Davies, Rebecca Roylance, Ellen Copson, Elena Provenzano, Karen Pinilla, Emma McMurtry, Marc Tischkowitz, Helena Margaret Earl
Journal: Journal of Clinical Oncology (2018)

TPS605 Background: No specific targeted therapies are available for triple negative breast cancer (TNBC), an aggressive and diverse subgroup. The basal TNBC subgroup show some phenotypic and molecular similarities with germline BRCA mutated BC (gBRCA). In gBRCA patients, and potentially other homologous recombination deficiencies, these already compromised pathways may allow PARP inhibitors to work more effectively. PARTNER was designed to establish if the addition of olaparib to neoadjuvant platinum-based chemotherapy for basal TNBC and/or gBRCA BC is safe and improves efficacy (pathological complete response (pCR)). Methods: Trial design: 3-Stage open label randomised Phase II/III trial of neoadjuvant CP: Carboplatin AUC5 with weekly Paclitaxel 80mg/m2 +/- olaparib 150mgBD for 12 days x 4 cycles, followed by clinicians' choice of anthracycline regimen x 3 cycles. Basal-TNBC and / or gBRCAm patients are eligible for inclusion. Tumour infiltrating lymphocytes and basal profile are assessed at baseline. Stage 1 and 2: Patients are randomised (1:1:1) to CP: CP + olaparib from day (D) –2: or CP + olaparib from D 3. Stage 3: Patients are randomised (1:1) to either control arm or to the research arm selected in stage 2. Primary end-points: Stage 1 – Safety; Stage 2 - Schedule selection criteria by pCR rate and completion rate of olaparib protocol treatment. 53 patients in each research arm will be evaluated within a “pick the winner” design. Null hypothesis of pCR ≤35% versus alternative hypothesis of pCR ≥55% will be tested with 90% power and 5% one sided significance level in each of the research arms. Stage 3 - Efficacy: anticipated pCR ~45-55% for all trial patients and ~50-60% for gBRCA patients. The trial is powered to detect an absolute improvement of 15% (all patients) and 20% (gBRCA patients) by adding olaparib to chemotherapy (enriched design). Enrichment design is applied with overall significance level 0.05(α) = 0.025(αall) + 0.025(αgBRCA) and 80% power. Current enrolment: 133 of planned 527 patients. Stage 1 accrual is complete. Stage 2 began in August 2017. 19 sites open and 12 more in active set-up. Clinical trial information: NCT03150576.
ARMY AND NAVY NEWS.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ACROMEGALY.
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reaching out to the depressed physician
Authors: T. E. Bittker
Journal: JAMA (1976)

Many of the character traits that contribute to physician success can become risk factors for depression when amplified. Only reluctantly do some physicians attend to and express personal needs. The preemptory desire to satisfy the demands of his patients and colleagues may further subvert selfawareness and appropriate self-indulgence. Ultimately, frank depression emerges. Too often, depression remains unrecognized or untreated until the physician's self-destructive pattern compromises his capacity to care for his patients. The author discusses clues to the early recognition of depression as well as strategies in the prevention and treatment of the depressed physician. (<i>JAMA</i>236:1713-1716, 1976)